Neurozen Inc.

1 clinical trials · Sponsor

Record	Firm	Date
Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients (NCT05383053)	Neurozen Inc.	2022-07-22

Every clearance here is in the API, with alerts when new ones post.